The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.
 
Leta Ko
No Relationships to Disclose
 
Michael B. Lilly
Research Funding - Bavarian Nordic (Inst)
 
Andrew W Hahn
No Relationships to Disclose
 
Roberto Nussenzveig
No Relationships to Disclose
 
Marcus Marie Moses
No Relationships to Disclose
 
Elisa Ledet
No Relationships to Disclose
 
Charlotte Manogue
No Relationships to Disclose
 
Patrick Cotogno
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Roche/Genentech (Inst); Sotio (Inst)
 
Brian E. Lewis
No Relationships to Disclose
 
Jodi Lyn Layton
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
A. Oliver Sartor
Stock and Other Ownership Interests - GlaxoSmithKline; Lilly; Noria Pharma Solutions
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Oncogenex; Pfizer; Progenics; Sanofi
Research Funding - Bayer (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Merck; Sanofi (Inst)
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Pedro C. Barata
No Relationships to Disclose